CY1120908T1 - Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης - Google Patents

Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης

Info

Publication number
CY1120908T1
CY1120908T1 CY181100988T CY181100988T CY1120908T1 CY 1120908 T1 CY1120908 T1 CY 1120908T1 CY 181100988 T CY181100988 T CY 181100988T CY 181100988 T CY181100988 T CY 181100988T CY 1120908 T1 CY1120908 T1 CY 1120908T1
Authority
CY
Cyprus
Prior art keywords
methods
systems
neurotoxin
chealth
cleansing
Prior art date
Application number
CY181100988T
Other languages
English (en)
Inventor
Curtis L Ruegg
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43879799&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CY1120908T1 publication Critical patent/CY1120908T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρουσιάζονται μέθοδοι και συστήματα για τον χρωματογραφικό καθαρισμό μιας νευροτοξίνης της αλλαντίασης. Αυτές οι μέθοδοι και τα συστήματα καθιστούν δυνατό τον αποτελεσματικό καθαρισμό μιας μη συμπλεγμένης μορφής της νευροτοξίνης της αλλαντίασης με υψηλό καθαρισμό και απόδοση, η οποία μπορεί να χρησιμοποιηθεί ως ενεργό συστατικό φαρμακευτικών σκευασμάτων.
CY181100988T 2009-10-21 2018-09-25 Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης CY1120908T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25381009P 2009-10-21 2009-10-21
PCT/US2010/053389 WO2011050072A1 (en) 2009-10-21 2010-10-20 Methods and systems for purifying non-complexed botulinum neurotoxin

Publications (1)

Publication Number Publication Date
CY1120908T1 true CY1120908T1 (el) 2019-12-11

Family

ID=43879799

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100988T CY1120908T1 (el) 2009-10-21 2018-09-25 Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης

Country Status (23)

Country Link
US (5) US20110092682A1 (el)
EP (1) EP2490986B2 (el)
JP (1) JP5951490B2 (el)
KR (1) KR101819129B1 (el)
CN (2) CN102666396B (el)
AU (1) AU2010310749B2 (el)
BR (1) BR112012009227A2 (el)
CA (1) CA2773396C (el)
CO (1) CO6551670A2 (el)
CY (1) CY1120908T1 (el)
DK (1) DK2490986T4 (el)
ES (1) ES2688065T3 (el)
HK (2) HK1175453A1 (el)
HR (1) HRP20181869T1 (el)
HU (1) HUE041599T2 (el)
IL (2) IL218532A (el)
LT (1) LT2490986T (el)
MX (3) MX2012004703A (el)
PL (1) PL2490986T3 (el)
PT (1) PT2490986T (el)
RS (1) RS58006B1 (el)
SI (1) SI2490986T1 (el)
WO (1) WO2011050072A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3332805T3 (da) 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
MX2012004703A (es) * 2009-10-21 2012-06-08 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
US20210162026A1 (en) 2017-08-28 2021-06-03 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3901163A4 (en) * 2018-12-21 2022-10-05 The Research Foundation for Microbial Diseases of Osaka University PROCESS FOR THE PRODUCTION OF BOTULINUM TOXIN
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102447441B1 (ko) * 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR20230009178A (ko) * 2021-07-08 2023-01-17 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US796419A (en) 1904-07-18 1905-08-08 Carl Halbig Doll-head.
SE303567B (el) * 1959-02-17 1968-09-02 Behringwerke Ag
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
ES2617692T3 (es) * 2000-07-21 2017-06-19 Revance Therapeutics, Inc. Sistemas de transporte de agentes biológicos de múltiples componentes
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB2386246B (en) 2001-11-01 2005-06-29 Marconi Applied Techn Ltd Electron beam tube apparatus
ATE494367T1 (de) * 2002-12-18 2011-01-15 Hoffmann La Roche Rekombinante desoxyribonuclease i aus rinder- pankreas mit hoher spezifischer aktivität
KR100498964B1 (ko) 2003-03-05 2005-07-01 삼성전자주식회사 이동단말에서의 전자파 흡수율 제어 방법 및 장치
AU2003271835A1 (en) * 2003-06-06 2005-01-04 Avecia Limited Process for the separation of proteins
WO2006096164A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
JP2007535911A (ja) * 2003-12-30 2007-12-13 バハラ バイオテック インターナショナル リミテッド 組換えタンパク質の製造及び精製方法
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
CA3031270A1 (en) * 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
EP1729821B1 (en) * 2004-03-03 2013-07-17 ReVance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4879978B2 (ja) * 2005-06-17 2012-02-22 メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー 生物活性化合物を発酵生産するための装置及び方法
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
ES2537579T3 (es) * 2006-10-27 2015-06-09 The Chemo-Sero-Therapeutic Research Institute Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante
CN100588706C (zh) * 2007-04-06 2010-02-10 常州千红生化制药股份有限公司 纯化弹性蛋白酶的方法
MX2009012570A (es) * 2007-06-01 2010-03-15 Merz Pharma Gmbh & Co Kgaa Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
DK3332805T3 (da) * 2008-12-31 2022-05-16 Revance Therapeutics Inc Injicerbare botulinumtoksinformuleringer
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
MX2012004703A (es) † 2009-10-21 2012-06-08 Revance Therapeutics Inc Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada.
US8440104B2 (en) * 2009-10-21 2013-05-14 General Electric Company Kimzeyite garnet phosphors
WO2013181576A2 (en) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods of evaluating and making biologics
US20140120077A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
JP6955491B2 (ja) * 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.

Also Published As

Publication number Publication date
US9469849B2 (en) 2016-10-18
PT2490986T (pt) 2018-11-13
KR20120099431A (ko) 2012-09-10
DK2490986T4 (da) 2024-06-17
CO6551670A2 (es) 2012-10-31
US20170029795A1 (en) 2017-02-02
WO2011050072A1 (en) 2011-04-28
MX2012004703A (es) 2012-06-08
SI2490986T1 (sl) 2018-12-31
KR101819129B1 (ko) 2018-02-28
US20120196349A1 (en) 2012-08-02
US11466262B2 (en) 2022-10-11
LT2490986T (lt) 2018-11-26
HK1215951A1 (zh) 2016-09-30
AU2010310749B2 (en) 2016-02-11
HK1175453A1 (en) 2013-07-05
EP2490986A1 (en) 2012-08-29
HRP20181869T1 (hr) 2019-01-11
US20110092682A1 (en) 2011-04-21
JP2013508388A (ja) 2013-03-07
AU2010310749A1 (en) 2012-03-29
EP2490986B2 (en) 2024-04-24
MX2019006519A (es) 2019-09-18
IL218532A (en) 2016-10-31
JP5951490B2 (ja) 2016-07-13
CN102666396B (zh) 2015-05-13
RS58006B1 (sr) 2019-02-28
IL248486A0 (en) 2016-12-29
CA2773396A1 (en) 2011-04-28
EP2490986B1 (en) 2018-08-08
BR112012009227A2 (pt) 2016-08-23
ES2688065T3 (es) 2018-10-30
IL218532A0 (en) 2012-07-31
US20200277591A1 (en) 2020-09-03
MX365496B (es) 2019-06-05
CN104961812A (zh) 2015-10-07
US20150322419A1 (en) 2015-11-12
DK2490986T3 (en) 2018-11-05
CA2773396C (en) 2020-12-15
CN102666396A (zh) 2012-09-12
EP2490986A4 (en) 2013-11-13
CN104961812B (zh) 2019-08-20
HUE041599T2 (hu) 2019-05-28
PL2490986T3 (pl) 2019-03-29

Similar Documents

Publication Publication Date Title
CY1120908T1 (el) Μεθοδοι και συστηματα για τον καθαρισμο της μη συμπλεγμενης νευροτοξινης της αλλαντιασης
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
WO2013078170A8 (en) Purification of anti-c-met antibodies
CY1121519T1 (el) Καθαρισμος της υδουρονικης-2-σουλφατασης
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
SG10201804869UA (en) Purification of biological molecules
MX346439B (es) Métodos y medios para modificar un genoma vegetal.
IN2014DN08481A (el)
BRPI0917993B8 (pt) composições de célula-tronco mesenquimal purificada
IN2012DN00801A (el)
BR112012005860A2 (pt) peptídeos isolados do veneno de aranha, e usos dos mesmos
WO2011036564A3 (en) Hyperblebbing shigella strains
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
MX2015008875A (es) Metodos para la purificacion de arilsulfatasa a.
CY1117288T1 (el) Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης
IN2014DN00161A (el)
UY33200A (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
BR112012017393A2 (pt) derivados de 2,5,7-oxazolpirimidina substituída
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.